IP Library › Granted Patent US 11,986,489
Granted Patent B2
US 11,986,489 · App. 17/167,428 · Granted May 21, 2024

Method of treating a disease using a glycolytic dependent compound

Inventors: James Galloway (Bridgewater, NJ); Tamara Byk-Tennenbaum (Kiryat Ono, IL); Erez Ilan (Kibbutz Netzer Sereni, IL); Lior Weissman (Nes-Ziona, IL); Sivan Doron (Moshav Arugot, IL); Eve Montia (Rehovot, IL)
Assignees: Ethicon, Inc.; Omrix Biopharmaceuticals Ltd.
A61K31/717A61K31/704A61L15/28A61L15/44A61L24/0015A61L24/0042A61L24/08A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,986,489
App. No.
17/167,428
Granted
May 21, 2024
Kind
B2
Abstract

The present invention is directed to methods of enhancing toxicity of a glycolytic dependent compound towards a cancerous tissue and/or organ in a subject, the method being comprised of targeting the glycolytic dependent compound to the cancerous tissue and/or organ by placing oxidized regenerated cellulose (ORC) and/or oxidized cellulose (OC) in direct connection with the cancerous tissue and/or organ, and administering the glycolytic dependent compound to the subject by a systemic route.

Claims (6)

1. A method of enhancing a destructive, inhibitive, and/or lethal effect of a glycolytic dependent compound towards cancerous cells in a tissue and/or organ in a subject, the method comprising the steps of:

A—targeting the glycolytic dependent compound to the cancerous tissue and/or organ by placing oxidized regenerated cellulose (ORC) and/or oxidized cellulose (OC) in direct connection with one or more cancerous cells in the tissue and/or organ, and

B—administering the glycolytic dependent compound to the subject by a systemic route,

wherein the ORC and/or OC and the glycolytic dependent compound are administered by different administration routes, and wherein the destructive, inhibitive, and/or lethal effect is enhanced as compared to a same dose of the glycolytic dependent compound administered in the absence of ORC/OC contact.

2. The method according to claim 1 , wherein the destructive, inhibitive, and/or lethal effect is enhanced by at least 1.20-times in the presence of the ORC and/or OC.

3. The method according to claim 1 , wherein the ORC and/or OC is contacted with the cancerous cell in the tissue and/or organ in a non-resected site.

Continuity (3)
Division 15234177 · Aug 11, 2016
Provisional Application 62205031 · Aug 14, 2015
Related Publication 20210154224A1 · May 27, 2021
Cited By (1)
US 12,364,785